← All science articles

· 2 min read

Defibrotide Shown to Act on Adenosine Receptors in Lab Experiments

By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer

Havdis Arctic PDRN95c against a stormy Norwegian coastline

Based on the PubMed abstract — the full text of this paper was not freely available.

Bianchi and colleagues, writing in the European Journal of Pharmacology in 1993, found that defibrotide, a single-stranded polydeoxyribonucleotide with known anti-clotting and anti-ischaemic properties, binds to adenosine receptors and produces effects similar to a known receptor-activating drug.

The researchers used laboratory binding experiments with radioactively labeled compounds to measure how defibrotide interacted with two types of adenosine receptors, called A1 and A2. Defibrotide displaced the labeled compounds in a dose-dependent, complete and competitive manner, with binding strengths (Ki values) of about 371 micrograms per milliliter at A1 receptors and 688 micrograms per milliliter at A2 receptors. Polydeoxyribonucleotides of different molecular weights bound similarly, but a double-stranded version and a negatively charged molecule with comparable charge did not bind, suggesting the single-stranded structure matters. In a separate tissue experiment using guinea-pig windpipe muscle, defibrotide relaxed muscle that had been contracted with potassium, with this effect blocked by a drug that blocks both A1 and A2 receptors but not by one that blocks only A1.

This is laboratory and isolated-tissue work only; it does not show effects in a whole animal or in people, and it does not address skin or wound applications.

Our reflection

This 1993 study is a foundational piece of pharmacology, identifying a specific receptor mechanism, adenosine receptor binding, through which a polydeoxyribonucleotide drug can act. It predates today's regenerative and dermatological PDRN research by decades, but it is part of the groundwork showing these molecules have defined, receptor-based biological activity. At Havdis, we see this kind of mechanistic clarity as part of what gives the broader PDRN field its scientific footing.

Source

Bianchi G, Barone D, Lanzarotti E, Tettamanti R, Porta R, Moltrasio D et al. (1993). European journal of pharmacology.

Read the paper on PubMedDOI: 10.1016/0014-2999(93)90864-e

This article is written by Havdis's AI Science Team to explain published research. It is not medical advice, and nothing here is a claim about any Havdis product.

From research to ingredient

Developing with PDRN? Let’s talk.